Discovery Of Highly Potent And Selective Î±4Î²2-Nicotinic Acetylcholine Receptor (Nachr) Partial Agonists Containing An Isoxazolylpyridine Ether Scaffold That Demonstrate Antidepressant-Like Activity. Part II by Yu, Li Fang et al.
Barrow Neurological Institute at St. Joseph's Hospital and Medical Center 
Barrow - St. Joseph's Scholarly Commons 
Neurobiology 
11-26-2012 
Discovery Of Highly Potent And Selective Î±4Î²2-Nicotinic 
Acetylcholine Receptor (Nachr) Partial Agonists Containing An 
Isoxazolylpyridine Ether Scaffold That Demonstrate 
Antidepressant-Like Activity. Part II 
Li Fang Yu 
J. Brek Eaton 
Allison Fedolak 
Han Kun Zhang 
Taleen Hanania 
See next page for additional authors 
Follow this and additional works at: https://scholar.barrowneuro.org/neurobiology 
Recommended Citation 
Yu, Li Fang; Eaton, J. Brek; Fedolak, Allison; Zhang, Han Kun; Hanania, Taleen; Brunner, Dani; Lukas, Ronald 
J.; and Kozikowski, Alan P., "Discovery Of Highly Potent And Selective Î±4Î²2-Nicotinic Acetylcholine 
Receptor (Nachr) Partial Agonists Containing An Isoxazolylpyridine Ether Scaffold That Demonstrate 
Antidepressant-Like Activity. Part II" (2012). Neurobiology. 206. 
https://scholar.barrowneuro.org/neurobiology/206 
This Article is brought to you for free and open access by Barrow - St. Joseph's Scholarly Commons. It has been 
accepted for inclusion in Neurobiology by an authorized administrator of Barrow - St. Joseph's Scholarly Commons. 
For more information, please contact molly.harrington@dignityhealth.org. 
Authors 
Li Fang Yu, J. Brek Eaton, Allison Fedolak, Han Kun Zhang, Taleen Hanania, Dani Brunner, Ronald J. Lukas, 
and Alan P. Kozikowski 
This article is available at Barrow - St. Joseph's Scholarly Commons: https://scholar.barrowneuro.org/neurobiology/
206 
Discovery of Highly Potent and Selective α4β2-Nicotinic
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like Activity. Part II
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†Drug Discovery Program, Department of Medicinal Chemistry and Pharmacognosy, University of Illinois at Chicago, 833 South
Wood Street, Chicago, Illinois 60612, United States
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ABSTRACT: In our continued efforts to develop α4β2-nicotinic acetylcho-
line receptor (nAChR) partial agonists as novel antidepressants having a
unique mechanism of action, structure−activity relationship (SAR)
exploration of certain isoxazolylpyridine ethers is presented. In particular,
modifications to both the azetidine ring present in the starting structure 4
and its metabolically liable hydroxyl side chain substituent have been
explored to improve compound druggability. The pharmacological character-
ization of all new compounds has been carried out using [3H]epibatidine
binding studies together with functional assays based on 86Rb+ ion flux
measurements. We found that the deletion of the metabolically liable hydroxyl group or its replacement by a fluoromethyl group
not only maintained potency and selectivity but also resulted in compounds showing antidepressant-like properties in the mouse
forced swim test. These isoxazolylpyridine ethers appear to represent promising lead candidates in the design of innovative
chemical tools containing reporter groups for imaging purposes and of possible therapeutics.
■ INTRODUCTION
Neuronal nAChRs are pentameric complexes assembled from
varying combinations of subunits (α2−α10, β2−β4) that
belong to the cys-loop superfamily of ligand-gated ion
channels.1,2 Each nAChR subunit consists of a large amino-
terminal extracellular domain (ECD), a transmembrane domain
comprising four α-helices (M1−M4), and a variable cytoplas-
mic domain between M3 and M4. Acetylcholine (ACh) binding
sites are formed between the subunit interfaces of the ECD
bound by the cys-loop containing, primary face of an α-type
subunit and the adjacent, complementary face of the
neighboring subunit. When acutely activated by endogenous
acetylcholine (ACh) or exogenous nicotinic ligands, nAChR
channels transiently open, allowing Na+, K+, and Ca2+ cations to
flow across the plasma membrane to induce cellular responses.
Prolonged exposure to ACh or nicotinic agonists causes a
gradual decrease in the rate of this ionic response, leading to a
high affinity, longer-lasting, functionally inactive state, via a
process referred to as desensitization. nAChRs are broadly
distributed in both the central and peripheral nervous systems,
and they can mediate excitatory neurotransmission and
modulate actions of other neurotransmitters, including the
monoamines dopamine (DA), norepinephrine (NE), and
serotonin (5-HT).3 Previous studies have shown that nAChRs
are promising targets for the treatment of depression, especially
for the patients who do not respond to selective serotonin
reuptake inhibitors (SSRIs).4−6
Among the nAChRs, β2 subunit-containing complexes (β2*-
nAChRs, where the * indicates that other nAChR subunits are
known or possible partners in the receptor assembly) are
believed to be involved in the antidepressant effects of some
nicotinic ligands and the tricyclic antidepressant (TCA)
amitriptyline. For example, β2 subunit-knockout mice show
decreased immobility compared to the wild-type mice in the
Porsolt forced swim test (FST), indicating that the absence of
β2*-nAChR-mediated signaling could manifest itself in an
antidepressant-like phenotype in vivo.7 Additionally, the
antidepressant-like effect of the nAChR antagonist mecamyl-
amine in the FST was diminished when the β2-subunit was
knocked out.8 Similarly, the antidepressant-like effects of the
nAChR agonist sazetidine-A and of the TCA amitriptyline were
absent in mice lacking the β2-subunit.7,9 Moreover, the activity
of citalopram and reboxetine in the mouse FST was enhanced
by agonists of α4β2*-nAChRs, suggesting the involvement of
β2-subunits in mediating these beneficial effects.10 Despite
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studies indicating that the S-enantiomer of mecamylamine
(TC-5214) that shows antidepressant-like effects in animal
models,11 recent phase III human trial findings assessing
efficacy of TC-5214 when used as an adjunct therapy in
patients that are nonresponders to treatment using the
traditional antidepressant citalopram failed to confirm earlier
indications of the ligand’s antidepressant potential.12 This
suggests that simple nAChR inactivation is not sufficient to
produce antidepressant effects in treatment-resistant patients,
although the lack of nAChR subtype specificity may also limit
TC-5214’s antidepressant efficacy. For example, although the
main ganglionic nAChR subtype (α3β4*-nAChRs) is expressed
at a relatively low level in the brain, blockade of α3β4*-nAChRs
may result in unwanted side effects in vivo, including
dysregulation of the autonomic nervous system, and α3β4*-
nAChRs also are sensitive to antagonism by mecamylamine.
Given these considerations, we continue to pursue ligands
highly selective for β2*-nAChRs as potential novel anti-
depressants, as do other groups in academia or the
pharmaceutical industry.
A-85380 (1) is a 3-pyridyl ether that exhibits high potency
and selectivity for α4β2-nAChRs (Ki = 0.05 nM for rat brain
receptors, 0.04 nM for human brain receptors) relative to
human α7-nAChRs (Ki = 148 nM) or muscle-type α1β1γδ-
nAChRs (Ki = 314 nM) (Figure 1).
13 Functionally, compound
1 acts as a potent activator of both the human α4β2-nAChRs
(EC50 = 0.7 μM) and ganglionic nAChRs (EC50 = 0.8 μM). It is
also a full agonist of human α7-nAChRs (EC50 = 8.9 μM)
compared to nicotine. Sazetidine-A (2), an analogue of
compound 1 having an alkynyl substituent attached to the 5-
position of the pyridine ring, was identified as a highly potent
partial α4β2-nAChR agonist. Compared to compound 1, its
selectivity relative to the ganglionic α3β4*- and homomeric α7-
nAChRs is highly improved. The robust antidepressant-like
effects of compound 2 were confirmed in the forced swim, tail
suspension, and novelty-induced hypophagia tests.9,14,15 How-
ever, the acetylenic bond in compound 2 may be oxidized to
generate a labile, highly reactive oxirene. This metabolic
transformation is a potential source of toxicity and discouraged
further advancement of compound 2. Novel analogues were
designed to avoid the acetylene functional group while
maintaining the important pharmacophoric elements of
compound 2. Previous work in our group has described the
discovery of a novel series of α4β2-nAChRs partial agonists via
replacing the metabolically unstable acetylene bond of
compound 2 with a substituted cyclopropane or isoxazole
ring, resulting in compounds 3 or 4, which exhibited
antidepressant-like efficacy in the mouse FST.16,17 Compound
4 is a highly selective α4β2-nAChR partial agonist with a Ki
value of 0.7 nM and an EC50 value of 36 nM. The favorable in
vitro and in vivo pharmacological profiles of these ligands
warrant further molecular optimization to create new
antidepressant drug candidates. In this paper, we describe the
synthesis, structure−activity relationship studies, and pharma-
cological evaluation of the isoxazolylpyridine ether series of
nAChR ligands. Selected compounds were further assessed in
behavioral tests relevant for the treatment of depression.
Rational Design and Synthesis of Isoxazolylpyridine
Ether nAChR Ligands. In our previous studies of analogues of
compound 4, we found that a side chain length of two or three
carbon atoms was optimal for biological activity.17 We thus
chose to synthesize the isoxazolylpyridine ether ligands bearing
a two or three carbon side chain counting from the isoxazole
ring to the hydroxyl group or other functional group at the
chain terminus. As compounds that contain hydroxyl groups
are generally prone to metabolic clearance via glucuronidation
and sulfation, we explored several approaches to lower this
probability of metabolism-related liabilities. Our initial effort
was to replace the hydroxyl group with a methoxy group. Given
that the length of the C−F bond (1.41 Å) is similar to that of
the C−O bond (1.43 Å), we next designed analogues in which
the hydroxyl group was replaced by a fluoromethyl or
difluoromethyl group. To better understand the SAR of the
right-hand chain, analogues featuring a terminal morpholine
ring, carbamate function, or alkyl group were designed.
The isoxazolylpyridine ether ligands 13, 18, 21, and 23−32
were synthesized utilizing the routes shown in Scheme 1. The
nitro compounds 9 and 11 were obtained in two steps from
commercially available 3-nitropropionic acid or 4-nitrobutyric
acid methyl ester. The desired isoxazoles 12, 15, 17, 20, and 22
were synthesized via 1,3-dipolar cycloaddition of nitrile oxides,
derived from the nitro compounds, to the previously reported
alkynes 5−7. Subsequent deprotection of the precursors 12, 17,
20, and 22 with TFA yielded the final compounds 13, 18, 21,
and 23. The preparation of compounds 24−32 proceeded
through the common intermediates 14, 16, and 19, which were
obtained by removal of the TBS group from 12, 15, or 17. The
methoxy analogue 24 was obtained from the alcohol 14 via
methylation and subsequent deprotection. The aldehyde
prepared from the alcohol 16 by Swern oxidation was
converted to a gem-difluoride using the stable and mild reagent,
(diethylamino)difluorosulfonium tetrafluoroborate (XtalFluor-
E), in conjunction with Et3N·3HF as a promoter. After removal
of the Boc group, the gem-difluoride 25 was obtained as its
trifluoroacetate salt. The primary alcohols 14, 16, and 19 were
transformed to the corresponding tosylates or iodides, followed
by nucleophilic substitution with tetrabutylammonium fluoride
(TBAF) or morpholine and removal of the Boc protecting
group to afford the derivatives 26, 27, and 28. The carbamate
analogues 29−32 were prepared by reaction of 14 or 19 with
the corresponding isocyanates. All the final compounds were
obtained as trifluoroacetates and were purified by HPLC. The
number of equivalents of TFA in these nonstoichiometric
compounds was determined by elemental analysis.
The syntheses of the isoxazolylpyridine ethers 38, 39, 42, and
43 are described in Scheme 2. Intermediate 34 was formed via
the Sonogashira coupling of 3-(benzyloxy)-5-bromopyridine
(33) and ethynyl(trimethyl)silane followed by the removal of
the TMS group. The alkyne 34 underwent 1,3-dipolar
cycloaddition with nitrile oxides to form the corresponding
isoxazoles 35−37. Sequential removal of the benzyl group and
Mitsunobu reaction with Boc-protected 2(S)-azetidinylmetha-
nol afforded the trifluoroacetates 38 and 39 after removal of the
Figure 1. Structures of A-85380 and some of its analogues.
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Boc group under acidic conditions. Compounds 42 and 43
were synthesized by employing the same strategy starting from
the commercially available amino acid 40 as shown in Scheme
2.
■ RESULTS AND DISCUSSION
In Vitro Characterization: Radioligand Binding Stud-
ies. In vitro binding affinities of the 17 compounds 13, 18, 21,
23−32, 38, 39, 42, and 43 were determined by the standard
[3H]epibatidine binding assay at seven rat nAChR subtypes.18
As shown in Table 1, these compounds generally demonstrated
good selectivity for the β2*-nAChRs (α2β2-, α3β2-, α4β2-, and
α4β2*-nAChRs) over the β4*-nAChRs (α3β4-, α2β4-, and
α4β4-nAChRs) compared to nicotine and varenicline. Most of
the compounds exhibited nanomolar or subnanomolar binding
affinities for both the α4β2- and α4β2*-nAChRs while showing
very weak binding affinity for α3β4-nAChRs with Ki values of
greater than 7000 nM, indicating that unwanted side effects
associated with the ganglionic α3β4-nAChR subtype would be
unlikely. The previously reported azetidine 13 is very potent at
β2*-nAChRs, with Ki values ranging from 0.6 to 15.4 nM. Ring
expansion of the azetidine ring to a pyrrolidine ring (compound
13 vs compound 18) resulted in at least 30-fold less potency at
all the β2*-nAChRs tested, including α2β2- (31.6 nM), α4β2-
(23.1 nM), and α4β2*-nAChRs (176 nM). N-Methylation on
the pyrrolidine ring (compound 23) restored the binding
affinities to those displayed by compound 13. Similarly, chain
elongation at the right-hand side alkoxy group of pyrrolidine 21
also gave low single-digit nanomolar binding affinities.
Replacement of the azetidine ring with the 3-azabicyclo[3.1.0]-
hex-2-yl group as in 42 and 43 resulted in more than a 300-fold
decrease in binding affinities at β2*-nAChRs (213 and 296 nM
at α4β2-nAChR). Taken together, the smaller azetidine ring
was found to give more potent binding at β2*-nAChRs
compared to the larger pyrrolidine or bicyclic amine rings, with
the exception of the N-methyl pyrrolidine 23.
In reference to the isoxazolyl side chain, the O-methylation of
compound 13 did not significantly alter binding affinities at the
β2*-nAChRs. Replacement of the terminal hydroxyl group with
mono-, di-, or trifluoro substituents (compounds 25, 26, and
39) in general maintained binding affinities. Deletion of the
hydroxyl group (compound 38) also resulted in similar binding
affinities, indicating that the hydroxyl group does not comprise
an essential pharmacophoric element for receptor recognition.
However, substitution of the hydroxyl group with an ionizable
morpholine ring (compound 27 vs 13, 28 vs 18) decreased the
binding affinities. Ring expansion of the azetidine 27 to the
pyrrolidine 28 gave a further decrease (approximately 3-fold) in
binding affinities, consistent with the previous observations
recorded for the pyrrolidine 18. The morpholine analogues 27
and 28 were inactive at all β4*-nAChRs (α2β4, α3β4, and
α4β4). Attachment of a carbamoyl group at the terminal
hydroxyl group (compounds 29−32) maintained, in general,
the subnanomolar to nanomolar binding affinities at the β2*-
nAChRs. In this carbamate series, the pyrrolidines 30 and 32
were again found to be approximately 5-fold less potent than
Scheme 1a
aReagents and conditions: (a) 9 or 11, PhNCO, Et3N, PhMe; (b)
TFA, CH2Cl2; (c) TBAF, THF; (d) NaH, CH3I, DMF; (e) (i)
(COCl)2, DMSO, CH2Cl2, (ii) XtalFluor-E, Et3N·3HF; (f) TsCl,
Et3N, DMAP, CH2Cl2; (g) I2, PPh3, imidazole, CH2Cl2; (h)
morpholine, CH3CN; (i) H2NR
1, PhNCO; (j) BH3·THF, THF; (k)
TBSCl, DMAP, Et3N, CH2Cl2.
Scheme 2a
aReagents and conditions: (a) ethynyl(trimethyl)silane, CuI,
PdCl2(PPh3)2, PPh3, Et3N, 60 °C; (b) TBAF, THF; (c) O2N-
(CH2)3CF3, O2N(CH2)2CH3, or 11, PhNCO, Et3N, PhMe; (d) 10%
Pd/C, H2; (e) 2-(hydroxymethyl)azetidine-1-carboxylic acid tert-butyl
ester, azodicarbonyldipiperidide (ADDP), nBu3P, PhMe; (f) TFA,
CH2Cl2; (g) (i) Boc2O, NaHCO3, THF, H2O, (ii) BH3·THF, THF;
(h) ADDP, nBu3P, 5-[3-[2-[tert-butyl(dimethyl)silyloxy]ethyl]-
isoxazol-5-yl]pyridin-3-ol, PhMe.
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the corresponding azetidines 29 and 31. Additionally, three of
the most potent α4β2- and α4β2*-nAChR ligands, 13, 25, and
38, were tested at α7- and α7*-nAChRs (α7*, endogenous
receptors prepared from rat forebrain), where they were found
to show no activity.
In Vitro Functional Characterization. In functional
studies, all compounds were tested using 86Rb+ ion efflux
assays and SH-EP1-hα4β2 (expressing human α4β2-nAChRs),
SH-SY5Y (α3β4*-nAChRs), or TE671/RD (α1β1γδ-nAChRs)
cells. Abilities of ligands to stimulate ion flux were characterized
as EC50 values, and inhibition by ligands following 10 min
preincubation on ion flux responses to a challenge concen-
tration of a nicotinic full agonist were characterized as
inactivation IC50 values. In general, the observed trends in
Table 1. Affinities of 17 Ligands for Rat nAChR Subtypes Defined by Competition for [3H]Epibatidine Binding
Ki (nM)
a
compd α2β2 α2β4 α3β2 α3β4 α4β2 α4β2*b α4β4
13 1.0 ± 0.2 935 15.4 ± 4.1 >104 0.6 ± 0.1 3.0 ± 0.4 1790
18 31.6 ± 4.0 2820 1080 NAd 23.1 ± 2.8 176 NA
21 4.8 ± 0.8 4266 72.4 ± 13 NA 6.8 ± 2.5 10.2 ± 2.7 1288
23 3.2 ± 0.7 2399 93 ± 22 NA 1.3 ± 0.4 16.2 ± 2.8 912
24 1.7 ± 0.2 3631 22.9 ± 4.6 NA 1.1 ± 0.2 4.9 ± 0.6 637
25 0.9 ± 0.1 1023 11.7 ± 2.4 >104 0.5 ± 0.1 4.0 ± 0.5 18.6 ± 2.8
26 1.0 ± 0.1 1445 19.5 ± 3.9 NA 0.4 ± 0.1 2.7 ± 0.3 170
27 12.3 ± 2.1 NA 117 ± 21 NA 11.0 ± 4.1 26.3 ± 6.8 NA
28 74 ± 13 NA 575 NA 32 ± 12 132 NA
29 1.4 ± 0.4 2042 12.3 ± 3.2 NA 0.5 ± 0.1 2.3 ± 0.3 355
30 5.8 ± 1.3 9550 87 ± 22 NA 2.3 ± 0.2 15.1 ± 2.3 1905
31 0.8 ± 0.2 513 9.8 ± 1.7 NA 0.4 ± 0.2 3.7 ± 1.0 102
32 6.2 ± 1.0 1413 60 ± 11 NA 2.0 ± 0.8 21.4 ± 5.5 513
38 0.5 ± 0.1 631 8.9 ± 1.8 7079 0.4 ± 0.1 1.7 ± 0.2 98 ± 14
39 1.1 ± 0.1 1188 33 ± 12 NA 0.6 ± 0.1 5.1 ± 0.6 300
42 285 NA 5967 NA 213 993 NA
43 449 NA 6433 NA 296 1313 NA
nicotinec 5.5 70 29 260 4.9 9.8 23
vareniclinee 86 0.4 110
aSee Experimental Section. SEM values are not provided for Ki values >100 nM.
bα4β2*, endogenous receptors prepared from rat forebrain. Besides
α4 and β2, other unidentified subunits may also be present. Details are provided in the Experimental Section. cKi values for nicotine are taken from
the PDSP Assay Protocol Book. dNA: not active, defined as <50% inhibition of binding in the primary assay at 10 μM. eKi values for varenicline are
from the literature.19
Table 2. Potencies and Efficacies of Ligand Agonism and Inactivation of Human α4β2-nAChRsa
agonism inactivation
compd EC50 (nM) pEC50 HS-α4β2 efficacy (%) LS-α4β2 efficacy (%) IC50 (nM) pIC50 inactivation efficacy (%)
13 43 7.37 ± 0.19 69 ± 5.6 −7.8 ± 3.8 32 7.50 ± 0.26 68 ± 4.9
18 >100 <7 NDb ND >100 ND ND
21 >100 <7 ND ND >100 ND ND
23 98 7.01 ± 0.08 65 ± 7.9 −3.1 ± 5.1 110 6.96 ± 0.04 76 ± 1.4
24 95 7.02 ± 0.42 60 ± 4.9 −1.5 ± 3.1 98 7.01 ± 0.18 79 ± 5.6
25 66 7.18 ± 0.28 56 ± 6.6 −2.4 ± 4.2 79 7.10 ± 0.19 80 ± 5.7
26 38 7.42 ± 0.38 61 ± 6.2 −3.6 ± 3.9 50 7.30 ± 0.19 79 ± 4.8
27 >100 <7 ND ND >100 ND ND
28 >100 <7 ND ND >100 ND ND
29 28 7.55 ± 0.08 30 ± 6.5 1.2 ± 2.9 50 7.30 ± 0.19 81 ± 4.9
30 >100 <7 ND ND >100 ND ND
31 35 7.45 ± 0.12 12 ± 6.1 4.8 ± 2.7 117 6.93 ± 0.21 85 ± 9
32 >100 <7 ND ND >100 ND ND
38 51 7.29 ± 0.34 84 ± 4.1 −2.7 ± 2.6 32 7.50 ± 0.15 74 ± 3.1
39 54 7.27 ± 0.11 29 ± 4.7 0.14 ± 1.5 83 7.08 ± 0.09 92 ± 2.7
42 >100 <7 ND ND >100 ND ND
43 >100 <7 ND ND >100 ND ND
nicotine 295 6.53 ± 0.05 124 ± 8.5 70 ± 5.9 427 6.37 ± 0.06 92 ± 2.1
varenicline 1096 5.96 ± 0.18 106 ± 5.9 34 ± 3.3 39 7.41 ± 0.08 83 ± 0.95
aSee Experimental Section for details. The term “inactivation” is used because compounds may be acting to desensitize receptors or as competitive
or noncompetitive antagonists, and further work is needed to make such a distinction. Potencies (EC50 or IC50 values) and efficacies were measured
for actions at a mixture of high-sensitivity (HS) and low-sensitivity (LS) α4β2-nAChRs. Reported errors are the standard error of the mean (SEM)
for all values. bND: not determined. The efficacy was not determined if the EC50 or the IC50 value was greater than 100 nM.
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the binding affinities presented in Table 1 carried over to the
functional assay data (Table 2). First, none of the ligands was
active at α3β4*- or α1β1γδ-nAChRs (EC50 or IC50 values were
>1000 nM; data not shown because of this lack of activity).
Acting at human α4β2-nAChRs (Table 2), azetidine 13
possesses an agonist EC50 value of 43 nM and an inactivation
IC50 value of 32 nM. Compound 18, which is the pyrrolidine
analogue of compound 13, was found to possess lower
functional activities (EC50 and IC50 values greater than 100
nM). However, in contrast to the trends observed in the
binding affinities for the pyrrolidines 21 and 23, which are
similar to those of compound 13, the functional activities of
these two compounds are lower than those of compound 13.
The methoxy analogue 24 was found to be 2-fold less active in
the EC50 agonism assay and 3-fold less active in the IC50
inactivation assay. The mono-, di- and trifluoro analogues 25,
26, and 39 all gave very similar EC50 values to that of the
azetidine 13, but with approximately 2-fold less active IC50
values. The morpholine analogues 27 and 28 were found to be
less active in the functional assays, consistent with the binding
data. For the carbamate series (compounds 29−32), the
azetidines 29 and 31 have EC50 values similar to that of
compound 13, whereas the corresponding pyrrolidines 30 and
32 have lower functional activities. The bicyclic ring substituted
analogues 42 and 43 were also found to be less active
functionally in comparison to compound 13, also consistent
with their binding profiles. Interestingly, the simple ethyl
analogue 38 showed the highest HS efficacy value of 84%, while
the carbamates exhibited the lowest HS efficacies (31, 12%; 29,
30%). None of the compounds displayed significant agonist or
antagonist activity at ganglionic α3β4*- or muscle-type α1β1γδ-
nAChRs, even at the highest concentration tested (10 μM).
It is informative to compare the SAR profile for the present
isoxazolylpyridine ether series (Tables 1 and 2) to that reported
previously for analogues of epibatidine (Figure 2). It has been
shown that the attachment of a phenyl ring to the 3-position of
the pyridine ring present in epibatidine maintains approx-
imately the same binding affinity at male rat cerebral cortex
nAChRs.20 This observed trend is consistent with our findings
showing that the incorporation of an isoxazole ring at the 5-
position of the isoxazolylpyridine scaffold does not dramatically
alter the binding affinities at α4β2-nAChRs (Table 1)
compared to the parent compound 1,13 with the exception of
the bicyclic amines 42 and 43. Table 2 shows that the majority
of the isoxazole-substituted analogues are potent partial
agonists at α4β2-nAChRs, while the parent compound 1 was
reported to be a potent, full agonist.21 Therefore, in the
pyridine−ether series, it can be concluded that the appendage
of an isoxazole ring to the 5-position of the pyridine ring
maintains binding affinities at α4β2-nAChRs while lowering the
functional efficacy.
In Vivo Behavioral Studies: Mouse Forced Swim Test.
Antidepressant efficacy was assessed with the mouse forced
swim test, an assay in which a mouse is placed into a beaker of
water, and the time spent passively floating in the water
(immobility) is recorded (Figure 3). Most traditional
antidepressants decrease the amount of time the mouse spends
immobile. Mice were administered compounds 25, 26, and 38
(5, 10, 30 mg/kg ip) or the SSRI antidepressant, sertraline, as a
positive control (20 mg/kg). Drug administration produced a
reduction in immobility, although it was not consistently dose-
dependent. Compound 38 was next tested at lower doses (1
and 3 mg/kg). Fisher’s post hoc tests showed that compounds
25, 26, and 38 reduced immobility at all three tested doses,
suggestive of antidepressant-like effects in vivo.
■ CONCLUSIONS
In this paper, we describe the synthesis, pharmacological
evaluation, and structure−activity relationships of a isoxazo-
lylpyridine ether series of nAChR ligands. The majority of
compounds belonging to this structural class were found to
bind to both α4β2- and α4β2*-nAChRs of rats with
significantly higher affinity (Ki values ranging from 0.4 to 176
nM) than to rat α3β4-nAChRs (Ki > 8000 nM). In functional
studies, these ligands acted as potent partial agonists at human
α4β2-nAChRs and were totally inactive at both ganglionic
α3β4*- or muscle-type α1β1γδ-nAChRs. SAR analyses suggest
that: (1) The appendage of an isoxazole ring to the 5-position
of the pyridine nucleus of compound 1 maintained the binding
affinities at α4β2-nAChRs while lowering functional agonist
efficacy, consistent with observations made in studies of some
epibatidine analogues. (2) The unsubstituted azetidine ring is
superior to the unsubstituted pyrrolidine ring for both binding
affinity and functional activity, which is consistent with our
previous findings. In the previously reported piperidylpyridine
ether series, no agonist activity was observed for either the N-
methyl or NH pyrrolidine analogues.22 On the contrary, in the
present isoxazolylpyridine ether series, the N-methyl pyrroli-
dine analogue 23 showed reasonable activity in the functional
studies although its NH analogue 18 did not. (3) The
unfunctionalized ethyl analogue 38 maintained biological
activity comparable to the alcohol 13, thus suggesting that
the hydroxyl group does not play an essential role in receptor
recognition. Moreover, methoxy, morpholine, carbamate, and
mono-, di-, or trifluoro analogues were also found to be
tolerated. In the mouse forced swim model, the difluoromethyl
group compound 25, fluoromethyl compound 26, and ethyl
compound 38 all demonstrated potent antidepressant-like
properties at all tested doses. Thus, the isoxazolylpyridine
ether scaffold functions as a versatile building block for
achieving selectivity for the α4β2- over the α3β4-nAChRs.
Various types of functionality can be built into this assembly in
order to alter ADMET parameters as well as to potentially
prepare compounds containing reporter groups for imaging
purposes. On the basis of this advantageous selectivity profile,
these α4β2-nAChR partial agonists warrant further study
directed toward the design of a host of innovative chemical
tools and potentially therapeutics.
Figure 2. Structural comparison of phenyl-bearing epibatidine
analogues and the isoxazolylpyridine ethers.
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■ EXPERIMENTAL SECTION
Chemical Synthesis. General Methods. Starting materials,
reagents, and solvents were purchased from commercial suppliers
and used without further purification unless otherwise stated.
Anhydrous THF and CH2Cl2 were obtained by distillation over
sodium wire or CaH2, respectively. All nonaqueous reactions were run
under an argon atmosphere with exclusion of moisture from reagents,
and all reaction vessels were oven-dried. The progress of reactions was
monitored by TLC on SiO2. Spots were visualized by their quenching
of the fluorescence of an indicator admixed to the SiO2 layer or by
dipping into KMnO4 solution followed by heating. SiO2 for column
chromatography (CC) was of 230−400 mesh particle size, and an
EtOAc/hexane mixture or gradient was used for elution unless stated
otherwise. 1H NMR spectra were recorded at a spectrometer
frequency of 300 or 400 MHz, 13C NMR spectra at 75 or 100
MHz, and 19F NMR spectra at 376 MHz. CDCl3.
1H chemical shifts
are reported in δ (ppm) using the δ 7.26 signal of CDCl3 or the δ 4.80
signal of D2O as internal standards.
13C chemical shifts are reported in
δ (ppm) using the δ 77.23 signal of CDCl3 as internal standard.
13C
NMR spectra in D2O were not adjusted. Purities of all final
compounds (>98%) were established by analytical HPLC, which
was carried out on an Agilent 1100 HPLC system with a Synergi 4 μ
Hydro-RP 80A column, with detection at 280 or 254 nm on a variable
wavelength detector G1314A; flow rate = 1.4 mL/min; gradient of 0−
100% methanol in water (both containing 0.05 vol % of TFA) in 18
min. Final products were purified by preparative HPLC under the
following conditions: column, ACE AQ, 250 mm × 20 mm; flow, 17
mL/min; all solvents containing 0.05 vol % TFA; UV detection at 254
and 280 nm. Gradient I: 0−50% MeOH in water in 20 min, to 100%
in 5 min, 100% for another 5 min, return to 0% in 5 min, and
equilibration at 0% for 1 min. Gradient II: 8−100% MeOH in water in
30 min, 100% for 5 min, return to 25% in 4 min, and equilibration at
8% for 1 min.
General Procedure for the [3 + 2] Cycloaddition to Form
Isoxazoles (Method A). To a solution of nitro compound (2.0−3.0
equiv) and alkyne (1.0 equiv) in anhydrous toluene were added phenyl
isocyanate (1.1 equiv) and triethylamine (1.1 equiv). The reaction
mixture was stirred at 60 °C for 12−48 h. The reaction mixture was
cooled to room temperature. After removal of the solvent, the residue
was purified by CC on SiO2 with hexane/acetone (2:1) to give the
isoxazoles.
General Procedure for the Deprotection of N-Boc-Amines to
Afford TFA Salts (Method B). To a solution of the N-Boc protected
precursor (1 mmol) in CH2Cl2 (10 mL) was added TFA (1 mL)
under argon with ice cooling. The mixture was stirred overnight at rt.
After the solvent was evaporated, the residue was dissolved in distilled
water (5 mL). The solution was filtered over a syringe filter
(polytetrafluoroethylene, 17 mm diameter, 0.45 μm pore size) and
then concentrated to 2−3 mL under reduced pressure at 30 °C bath
temperature. The crude product was purified by preparative HPLC.
After the solvent was evaporated, the residue was dissolved in distilled
water (about 2−3 mL). The solution was lyophilized to obtain the
TFA salt.
General Procedure for the Deprotection of TBS Ethers to Afford
Free Alcohols (Method C). To a solution of the TBS-protected alcohol
precursor (1 mmol) in THF (10 mL) was added 1 M
tetrabutylammonium fluoride (TBAF) in THF (1 mL) under argon
with ice cooling. After the mixture was stirred for 30 min at rt, it was
diluted with water (20 mL) under ice cooling. The mixture was
extracted with EtOAc (2 × 30 mL), dried over anhydrous Na2SO4,
filtered, and concentrated under vacuum. The residue was purified by
CC on SiO2 to give the alcohol.
General Procedure for the Preparation of Iodides from Alcohols
(Method D). To a stirred solution of an alcohol (1 mmol), imidazole
(1.5 mmol), and PPh3 (1.5 mmol) in anhydrous PhMe (8 mL) was
added I2 (1.5 mmol) with ice cooling under argon. After stirring
overnight at rt, the solvent was evaporated. The residue was purified
by CC on SiO2 to give the iodide.
General Procedure for the Preparation of Morpholines from
Iodides (Method E). To a solution of an iodide (1 mmol) in
anhydrous CH3CN (10 mL) was added morpholine (4 mmol) at rt.
After stirring overnight, the reaction mixture was concentrated. The
residue was purified by CC on SiO2 (CH2Cl2/MeOH) to obtain the
product.
Figure 3. Compounds 25, 26, and 38 reduced immobility in the mouse forced swim test at all tested doses (5, 10, and 30 mg/kg for compounds 25
and 26; 1, 3, 5, 10, and 30 mg/kg for compound 38). The SSRI, sertraline, produced the expected decrease in immobility. ANOVAs: F (4, 41) =
44.49, p < 0.0001 (top left); F (4, 42) = 23.40, p < 0.0001 (top right); F (4, 44) = 35.99, p < 0.0001 (bottom left); F (4, 44) = 32.57, p < 0.0001
(bottom right). Fisher’s PLSD posthoc test: **ps < 0.0001 vs vehicle; *ps < 0.05 vs vehicle). n = 9−10/group.
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General Procedure for the Preparation of Carbamates from
Alcohols 14 and 19 (Method F). A solution of 14 or 19 (1 mmol),
isocyanate (2 mmol), and 4-(dimethylamino)pyridine (DMAP; 0.1
mmol) in anhydrous toluene (5 mL) was stirred at 80 °C under Ar for
5 h. The solvent was removed under reduced pressure, and the residue
was purified by CC on SiO2 (acetone/hexane) to obtain the product.
General Procedure for O-Debenzylation to Afford Hydroxypyr-
idines (Method G). To a solution of the Bn-protected hydroxypyridine
(1 mmol) in MeOH (10 mL) was added 10% Pd/C (10%). A H2
balloon was connected after the atmosphere was exchanged three
times with Ar. The reaction was allowed to proceed at rt for 2 h, then
the catalyst was filtered off over Celite. The filtrate was evaporated,
and the residue was purified by CC on SiO2 (CHCl3/MeOH 30:1) to
furnish the hydroxypyridine as a colorless oil.
General Procedure for the Mitsunobu Reaction of 2-
(Hydroxymethyl)azetidine-1-carboxylic Acid tert-Butyl Ester or
Compound 41 with Hydroxypyridines to Afford Alkoxylpyridines
(Method H). In a 100 mL side arm flask with stir bar and argon
balloon, tri-n-butylphosphine (1 mmol) was added dropwise in 5 min
to a solution of N,N′-azodicarbonyldipiperidine (1 mmol) in
anhydrous toluene (5 mL). Stirring was continued at rt for 30 min
to complete the formation of the Mitsunobu reagent. A solution of the
hydroxypyridine intermediate (0.6 mmol) and 2-(hydroxymethyl)-
azetidine-1-carboxylic acid tert-butyl ester or 41 (1 mmol) in
anhydrous toluene (10 mL) was added to the Mitsunobu reagent at
0 °C within 45 min. The mixture was warmed to rt and stirred
overnight. After removal of the solvent, the residue was purified by CC
on SiO2 (hexane/EtOAc 2:1 to 1:1) to furnish the desired product.
General Procedure for the Reduction of Acids or Acid Esters to
Alcohols (Method I). To a solution of acid or acid ester (4 mmol) in
20 mL anhydrous THF was added under argon with ice cooling a 1 M
solution of borane in THF (5 mL). The reaction mixture was stirred
overnight at rt and then quenched with satd NH4Cl solution followed
by extraction with EtOAc (2 × 20 mL). The combined organic layers
were washed with water and brine, dried over Na2SO4, and evaporated
to obtain the alcohol, which was used without further purification.
General Procedure for the Protection of Alcohols with TBS
(Method J). To a solution of alcohol (3 mmol) and TBSCl (3 mmol)
in 20 mL of anhydrous CH2Cl2 were added DMAP (0.1 mmol) and
Et3N (3 mmol). The reaction mixture was stirred overnight at rt. After
removal of the solvent, the residue was purified by CC on SiO2
(hexane/EtOAc 4:1) to obtain the desired product.
2(S)-[(5-Ethynylpyridin-3-yloxy)methyl]pyrrolidine-1-carboxylic
Acid tert-Butyl Ester (6) and 3-Ethynyl-5-[(1-methyl-2(S)-
pyrrolidinyl)methoxy]pyridine (7). These two compounds were
synthesized according to the previously reported methods for
compound 5.17 Compound 6: 1H NMR (400 MHz, CDCl3) δ 8.01
(br, 2H), 7.11 (br, 1H), 3.93−3.67 (m, 3H), 3.13 (m, 3H), 1.80−1.65
(m, 4H), 1.26 (s, 9H). Compound 7: 1H NMR (400 MHz, CDCl3) δ
8.26 (s, 1H), 8.23 (s, 1H), 7.24 (s, 1H), 3.95 (m, 1H), 3.88 (m, 1H),
3.17 (s, 1H), 3.07 (t, 1H, J = 8.0 Hz), 2.62 (m, 1H), 2.42 (s, 3H), 2.27
(m, 1H), 1.98 (m, 1H), 1.78−1.52 (m, 3H). 13C NMR (100 MHz,
CDCl3): δ 154.6, 145.1, 138.3, 123.8, 119.5, 80.6, 80.3, 71.3, 64.2, 57.8,
41.8, 28.6, 23.1.
tert-Butyl(dimethyl)(3-nitropropoxy)silane (9). This compound
was obtained from 8 employing methods I and J; pale-yellow oil;
yield 56% over two steps. 1H NMR (400 MHz, CDCl3) δ 4.50 (t, 2H,
J = 6.8 Hz), 3.71 (t, 2H, J = 5.6 Hz), 2.20 (m, 2H), 0.89 (s, 9H), 0.05
(s, 6H).
tert-Butyl(dimethyl)(4-nitrobutoxy)silane (11). This compound
was obtained from 10 employing methods I and J; pale- yellow oil;
yield 62% in two steps. 1H NMR (400 MHz, CDCl3) δ 4.43 (t, 2H, J =
6.0 Hz), 3.66 (t, 2H, J = 4.0 Hz), 2.10 (m, 2H), 1.60 (m, 2H), 0.90 (s,
9H), 0.06 (s, 6H).
2-[5-[5-((S)Azetidin-2-ylmethoxy)-3-pyridinyl]-3-isoxazolyl]-
ethanol (13). This compound was obtained from 1217 employing
method B and gradient I; colorless oil; yield 36% over two steps;
purity 99.7%; [α]D
20 −3.6 (c = 0.72, MeOH). 1H NMR (400 MHz,
D2O) δ 8.94 (s, 1H), 8.67 (s, 1H), 8.59 (s, 1H), 7.12 (s, 1H), 5.03−
5.01 (m, 1H), 4.65 (d, 2H, J = 2.0 Hz), 4.17−4.08 (m, 1H), 3.94 (t,
2H, J = 6.0 Hz), 3.00 (t, 2H, J = 6.4 Hz), 2.75−2.69 (m, 2H). 13C
NMR (100 MHz, D2O) δ 163.4, 162.6, 162.3 (TFA), 156.3, 131.7,
130.0, 127.5, 127.4, 115.8 (TFA), 104.2, 67.7, 58.9, 58.1, 43.3, 28.0,
19.8. Anal. Calcd for C14H17N3O3·1.65TFA·0.7H2O (FW 476): C,
43.65; H, 4.25; F, 19.75; N, 8.83. Found: C, 43.28; H, 3.87; F, 19.53;
N, 8.56.
2(S)-[[5-[3-(2-Hydroxyethyl)-5-isoxazolyl]-3-pyridinyloxy]methyl]-
azetidine-1-carboxylic Acid tert-Butyl Ester (14). 1H NMR (400
MHz, CDCl3) δ 8.48 (s, 1H), 8.28 (s, 1H), 7.53 (s, 1H), 6.55 (s, 1H),
4.48 (m, 1H), 4.32 (m, 1H), 4.11 (dd, 2H, J = 2.8, 10.0 Hz), 3.92 (t,
2H, J = 6.0 Hz), 3.83 (t, 2H, J = 7.6 Hz), 3.65 (br, 1H), 2.91(t, 2H, J =
6.2 Hz), 2.33−2.21 (m, 2H), 1.33 (s, 9H).
2(S)-[[5-[3-[3-[tert-Butyl(dimethyl)silanyloxy]propyl]-5-isoxazol-
yl]-pyridin-3-yloxy]methyl]azetidine-1-carboxylic Acid tert-butyl
Ester (16). This was obtained from 1517 employing method C;
colorless oil; yield 62%. 1H NMR (400 MHz, CDCl3) δ 8.48 (s, 1H),
8.27 (s, 1H), 7.49 (s, 1H), 6.44 (s, 1H), 4.42 (m, 1H), 4.28 (m, 1H),
4.07 (m, 1H), 3.76 (t, 2H, J = 7.0 Hz), 3.66 (br, 1H), 3.60 (m, 2H),
2.72 (t, 2H, J = 7.8 Hz), 2.29−2.18 (m, 2H), 1.85 (m, 2H), 1.26 (s,
9H). 13C NMR (100 MHz, CDCl3) δ 171.0, 166.4, 164.4, 156.1, 139.3,
117.4, 100.8, 79.7, 68.8, 61.1, 60.2, 47.2, 30.9, 28.2, 22.5, 20.9, 18.9,
14.0.
2(S)-[[5-[3-[2-[tert-Butyl(dimethyl)silanyloxy]ethyl]-5-isoxazolyl]-
pyridin-3-yloxy]methyl]pyrrolidine-1-carboxylic Acid tert-Butyl Ester
(17). 1H NMR (400 MHz, CDCl3) δ 8.53 (s, 1H), 8.30 (s, 1H), 7.66−
7.50 (m, 1H), 6.56 (s, 1H), 4.40−3.98 (m, 3H), 3.89 (t, 2H, J = 6.0
Hz), 3.38−3.29 (m, 2H), 2.89 (t, 2H, J = 6.0 Hz), 1.66−1.59 (m, 4H),
1.46 (s, 9H), 0.84 (s, 9H), 0.00 (s, 6H).
2-[5-[5-(2(S)Pyrrolidinylmethoxy)-3-pyridinyl-3-isoxazolyl]-
ethanol (18). This compound was obtained from 17 employing
method B and gradient I; colorless oil; yield 31% over two steps;
purity 99.6%; [α]D
20 4.8 (c = 0.99, MeOH). 1H NMR (400 MHz,
D2O) δ 8.94 (s, 1H), 8.64 (s, 1H), 8.54 (s, 1H), 7.13 (s, 1H), 4.70
(dd, 2H, J = 10.4, 3.2 Hz), 4.49 (dd, 2H, J = 10.0, 7.6 Hz), 4.20 (m,
1H), 3.96 (t, 2H, J = 8.0 Hz), 3.44 (t, 2H, J = 7.2 Hz), 3.02 (t, 2H, J =
6.2 Hz), 2.33 (m, 1H), 2.17−2.11 (m, 2H), 2.02−1.97 (m, 1H). 13C
NMR (100 MHz, D2O) δ 163.4, 162.7, 162.4 (TFA), 156.2, 131.9,
127.4, 127.2, 115.8 (TFA), 104.1, 67.8, 58.9, 57.9, 45.6, 28.0, 25.4,
23.0. Anal. Calcd for C15H19N3O3·2.35TFA (FW 557): C, 42.46; H,
3.86; F, 24.03; N, 7.54. Found: C, 42.66; H, 3.85; F, 24.17; N, 7.68.
2(S)-[[5-[3-(2-Hydroxyethyl)-5-isoxazolyl]-3-pyridinyloxy]methyl]-
pyrrolidine-1-carboxylic Acid tert-Butyl Ester (19). 1H NMR (400
MHz, CDCl3) δ 8.52 (s, 1H), 8.29 (s, 1H), 7.70−7.57 (m, 1H), 6.62−
6.57 (m, 1H), 4.22−4.12 (m, 3H), 3.97−3.89 (m, 3H), 3.36−3.31 (m,
3H), 2.72 (t, 2H, J = 6.2 Hz), 1.95−1.84 (m, 2H), 1.42 (s, 9H).
3-[5-[5-(2(S)-Pyrrolidinylmethoxy)-3-pyridinyl]-3-isoxazolyl]-1-
propanol (21). This compound was obtained from 6 and 11
employing methods A and B and gradient I; colorless oil; yield 31%
over two steps; purity 99.7%; [α]D
20 5.4 (c = 0.5, MeOH). 1H NMR
(400 MHz, D2O) δ 8.92 (s, 1H), 8.63 (s, 1H), 8.53 (s, 1H), 7.08 (s,
1H), 4.69 (dd, 2H, J = 10.8, 3.2 Hz), 4.49 (dd, 2H, J = 10.4, 7.6 Hz),
4.20 (m, 1H), 3.66 (t, 2H, J = 6.4 Hz), 3.44 (t, 2H, J = 7.2 Hz), 2.84 (t,
2H, J = 7.6 Hz), 2.32 (m, 1H), 2.11−2.00 (m, 2H), 2.00−1.94 (m,
1H). 13C NMR (100 MHz, D2O) δ 165.4, 162.5, 162.2 (TFA), 156.2,
131.7, 129.9, 127.5, 127.2, 117.3 (TFA), 104.0, 67.8, 60.2, 57.9, 45.6,
4 1 . 2 , 2 9 . 2 , 2 5 . 4 , 2 3 . 0 , 2 1 . 5 . A n a l . C a l c d f o r
C16H21N3O3·1.8TFA·0.8H2O (FW 523): C, 45.01; H, 4.70; F,
19.62; N, 8.03. Found: C, 45.10; H, 4.47; F, 19.76; N, 7.81.
2-[5-[5-[(1-Methyl-2(S)-pyrrolidinyl)methoxy]-3-pyridinyl]-3-
isoxazolyl]ethanol (23). This compound was obtained from 7 and 9
employing methods A and B and gradient I; colorless oil; yield 14% in
two steps; purity 99.5%; [α]D
20 −2.3 (c = 0.61, MeOH). 1H NMR
(400 MHz, D2O) δ 8.91 (s, 1H), 8.61 (s, 1H), 8.53 (s, 1H), 7.08 (s,
1H), 4.70 (dd, 1H, J = 2.6, 11.2 Hz), 4.54 (dd, 1H, J = 6.0, 10.8 Hz),
3.96 (m, 1H), 3.90 (t, 2H, J = 6.0 Hz), 3.73 (m, 1H), 3.22 (m, 1H),
3.02 (s, 3H), 2.97 (t, 2H, J = 6.2 Hz), 2.39 (m, 1H), 2.18 (m, 1H),
2.08 (m, 2H). 13C NMR (100 MHz, D2O) δ 163.4, 162.4, 162.3
(TFA), 156.1, 131.8, 129.8, 127.5, 127.4, 115.7 (TFA), 104.2, 66.8,
66.5, 58.9, 56.8, 40.2, 28.0, 25.4, 21.7. Anal. Calcd for
C16H21N3O3·2.6TFA (FW 556): C, 42.45; H, 3.97; N, 7.01. Found:
C, 42.47; H, 3.78; N, 7.01.
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3-(2(S)-Azetidinylmethoxy)-5-[3-(2-methoxyethyl)-5-isoxazolyl]-
pyridine (24). To a solution of compound 14 (150 mg, 0.4 mmol) in
anhydrous DMF (3 mL) were added NaH (32 mg, 0.8 mmol, 60% in
oil) under argon with ice cooling. After stirring at rt for 30 min, CH3I
was added. The reaction mixture was quenched with satd NH4Cl and
extracted with EtOAc (20 mL). The organic phase was washed with
water (2 × 15 mL), dried over Na2SO4, and concentrated. The residue
was purified by CC on SiO2 (hexane/EtOAc) to obtain 2-[[5-[3-(2-
methoxyethyl)isoxazol-5-yl]pyridin-3-yloxy]methyl]azetidine-1-car-
boxylic acid tert-butyl ester (130 mg, 84%) as a colorless oil. 1H NMR
(400 MHz, CDCl3) δ 8.56 (s, 1H), 8.33 (s, 1H), 7.56 (s, 1H), 6.54 (s,
1H), 4.50 (m, 1H), 4.35 (m, 1H), 4.15 (dd, 1H, J = 2.4, 10.0 Hz), 3.85
(t, 2H, J = 7.6 Hz), 3.66 (t, 2H, J = 6.2 Hz), 3.34 (s, 3H), 2.95 (t, 2H, J
= 6.4 Hz), 2.35−2.22 (m, 2H), 1.36 (s, 9H). 13C NMR (100 MHz,
CDCl3) δ 166.7, 152.5, 156.3, 155.2, 139.7, 139.5, 124.3, 117.6, 101.3,
79.9, 70.5, 58.8, 47.4, 28.5, 26.8, 19.2.
The title compound was obtained from the preceding intermediate
employing method B and gradient I; colorless oil; yield 45%; purity
99.7%; [α]D
20 −3.5 (c = 0.97, MeOH). 1H NMR (400 MHz, D2O) δ
8.91 (s, 1H), 8.67 (d, 1H, J = 1.6 Hz), 8.56 (s, 1H), 7.09 (s, 1H), 5.01
(m, 1H), 4.64 (d, 2H, J = 3.6 Hz), 4.12 (m, 2H), 3.79 (t, 2H, J = 6.0
Hz), 3.34 (s, 3H), 3.02 (t, 2H, J = 6.0 Hz), 2.71 (q, 2H, J = 8.4 Hz).
13C NMR (100 MHz, D2O) δ 163.3, 162.6, 161.7 (TFA), 156.3, 131.7,
130.1, 127.4, 127.3, 115.9 (TFA), 104.1, 69.1, 67.7, 58.2, 57.4, 43.3,
40.5, 25.3, 19.8. Anal. Calcd for C15H19N3O3·2.05TFA·1H2O (FW
541): C, 42.40; H, 4.29; F, 21.59; N, 7.77. Found: C, 42.21; H, 4.09; F,
21.41; N, 7.82.
3-(2(S)-Azetidinylmethoxy)-5-[3-(3,3-difluoropropyl)-5-
isoxazolyl]pyridine (25). To a solution of oxalyl chloride (54 μL, 0.61
mmol) in anhydrous CH2Cl2 (5 mL) was added dropwise at −78 °C, a
solution of anhydrous DMSO (54 μL, 0.72 mmol) in anhydrous
CH2Cl2 (2 mL). This Swern reagent solution was stirred for another
15 min at the same temperature. A solution of alcohol 16 (140 mg,
0.36 mmol) in anhydrous CH2Cl2 (2 mL) was added in 10 min. After
stirring for 20 min, Et3N (310 μL, 2.2 mmol) was added within 5 min.
After maintaining the temperature for another 20 min, the reaction
mixture was warmed slowly to rt. The mixture was washed with water
(2 × 5 mL), dried over Na2SO4, and concentrated to obtain the
aldehyde, which was carried on without further purification.
To a solution of triethylamine trihydrofluoride (120 μL, 0.72 mmol)
in CH2Cl2 (2 mL) was successively added XtalFluor-E (125 mg, 0.54
mmol). A solution of the crude aldehyde in anhydrous CH2Cl2 (2 mL)
was slowly added, and the resulting mixture was stirred at rt for 2 h
under argon. The reaction mixture was quenched with 5% aqueous
Na2CO3 solution and extracted with CH2Cl2 (20 mL). The combined
organic layers were washed with H2O, brine, dried over Na2SO4, and
evaporated. The residue was purified by CC on SiO2 (hexane/acetone
4:1) to afford the desired product (105 mg, 71%, two steps) as a
colorless oil. 1H NMR (400 MHz, CDCl3) δ 8.56 (s, 1H), 8.36 (s,
1H), 7.59 (s, 1H), 6.50 (s, 1H), 5.94 (tt, 1H, JH−H = 4.2 Hz, JH−F =
56.4 Hz), 4.51 (m, 1H), 4.38 (m, 1H), 4.17 (dd, J = 2.8, 10.0 Hz), 3.87
(t, 2H, J = 7.6 Hz), 2.89 (t, 2H, J = 8.4 Hz), 2.37−2.20 (m, 4H), 1.38
(s, 9H). 13C NMR (100 MHz, CDCl3) δ 167.3, 162.8, 156.4, 155.3,
140.0, 139.5, 124.1, 117.7, 116.2 (t, JC−F = 240.0 Hz), 100.6, 80.0, 69.1,
60.1, 47.3, 32.3 (t, JC−F = 21.8 Hz), 28.5, 19.3 (t, JC−F = 6.4 Hz), 19.2.
19F NMR (376 MHz, CDCl3) δ −117.4 (dt, 2F, JH−F = 56.6, 17.1 Hz).
The title compound was obtained from the preceding intermediate
employing method B and gradient II; colorless oil; yield 65%; purity
99.7%; [α]D
20 −2.8 (c = 1.2, MeOH). 1H NMR (400 MHz, D2O) δ
8.90 (s, 1H), 8.68 (s, 1H), 8.52 (s, 1H), 6.05 (t, 1H, JH−F = 56.2 Hz),
5.04 (m, 1H), 4.65 (d, 2H, J = 3.2 Hz), 4.15 (m, 2H), 2.95 (t, 2H, J =
5.8 Hz), 2.74 (q, 2H, J = 8.4 Hz), 2.30 (m, 2H). 13C NMR (100 MHz,
D2O) δ 164.3, 162.8, 162.3 (TFA), 132.2, 130.6, 127.1, 126.7, 116.6 (t,
JC−F = 240.0 Hz), 115.8 (TFA), 103.8, 67.6, 58.1, 43.3, 30.8 (t, JC−F =
21.4 Hz), 19.9, 18.0 (t, JC−F = 6.6 Hz).
19F NMR (376 MHz, D2O) δ
−75.6 (TFA), −117.3 (dt, 2F, JH−F = 56.4, 18.8 Hz). Anal. Calcd for
C15H17F2N3O2·1.9TFA·0.75H2O (FW 539): C, 41.86; H, 3.81; F,
27.12; N, 7.79. Found: C, 42.01; H, 3.84; F, 27.23; N, 7.61.
3-(2(S)-Azetidinylmethoxy)-5-[3-(3-fluoropropyl)-5-isoxazolyl]-
pyridine (26). To the solution of 16 (200 mg, 0.5 mmol), DMAP (6
mg, 0.05 mmol), and Et3N (0.17 mL, 1.25 mmol) in 10 mL of
anhydrous CH2Cl2 was added under argon with ice cooling p-TsCl
(130 mg, 0.65 mmol). The reaction mixture was stirred overnight at rt.
Purification by CC on SiO2 (hexane/EtOAc) afforded the
intermediate p-toluenesulfonate (240 mg, 86%) as a colorless oil. 1H
NMR (400 MHz, CDCl3) δ 8.46 (s, 1H), 8.28 (s, 1H), 7.66 (d, 2H, J
= 8.0 Hz), 7.49 (s, 1H), 7.21 (d, 2H, J = 7.6 Hz), 6.37 (s, 1H), 4.44
(m, 1H), 4.31 (m, 1H), 4.09 (dd, 1H, J = 1.2, 10.0 Hz), 4.02 (t, 2H, J
= 6.0 Hz), 3.79 (t, 2H, J = 7.4 Hz), 2.67 (t, 2H, J = 7.4 Hz), 2.30 (s,
3H), 2.26−2.21 (m, 2H), 1.99 (m, 2H), 1.30 (s, 9H). 13C NMR (100
MHz, CDCl3) δ 166.7, 163.0, 156.1, 155.1, 144.8, 139.6, 139.2, 132.7,
129.8, 127.7, 117.3, 100.6, 79.6, 69.2, 68.8, 60.0, 53.5, 47.1, 43.9, 28.3,
27.1, 22.1, 21.5, 19.0. To a solution of the above p-toluenesulfonate
(240 mg, 0.44 mmol) in 2 mL of anhydrous THF was added at rt 1 M
TBAF in THF (3 mL, 3 mmol). After stirring for 3 h, the reaction
mixture was quenched with satd NH4Cl and extracted with EtOAc (2
× 15 mL). The combined organic phases were washed with brine,
dried over Na2SO4, and evaporated. The residue was purified by CC
on SiO2 (CH2Cl2/MeOH 98:2) to afford the desired product (110
mg, 64%) as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 8.51 (s,
1H), 8.30 (s, 1H), 7.54 (s, 1H), 6.45 (s, 1H), 4.45 (dt, 1H, JH−F = 46.8
Hz, JH−H = 5.8 Hz), 4.46 (m, 1H), 4.33 (m, 1H), 4.12 (dd, 1H, J = 2.8,
10.0 Hz), 3.81 (t, 2H, J = 7.6 Hz), 2.79 (t, 2H, J = 7.6 Hz), 2.30 (m,
2H), 2.04 (m, 2H), 1.32 (s, 9H). 13C NMR (100 MHz, CDCl3) δ
166.8, 163.6, 156.2, 155.2, 139.7, 139.3, 124.1, 117.5, 100.7, 82.7 (d,
JC−F = 164.8 Hz), 79.7, 68.9, 60.2, 53.6, 43.9, 28.8 (d, JC−F = 20.1 Hz),
28.4, 22.1 (d, JC−F = 5.5 Hz), 19.0.
The title compound was obtained from the preceding intermediate
employing method B and gradient II; colorless oil; yield 97%; purity
99.4%; [α]D
20 −3.2 (c = 1.99, MeOH). 1H NMR (400 MHz, D2O) δ
8.89 (s, 1H), 8.67 (s, 1H), 8.52 (s, 1H), 7.07 (s, 1H), 5.03 (m, 1H),
4.66−4.60 (m, 3H), 4.50 (t, 1H, J = 5.4 Hz), 4.15 (m, 2H), 2.87 (t,
2H, J = 7.4 Hz), 2.74 (t, 2H, J = 8.4 Hz), 2.17−2.04 (m, 2H). 13C
NMR (100 MHz, D2O) δ 165.4, 163.0, 162.3 (TFA), 156.5, 132.4,
130.9, 127.6, 127.1, 115.5 (TFA), 104.3, 83.9 (d, JC−F = 158.4 Hz),
68.0, 58.5, 43.7, 27.9 (d, JC−F = 19.5 Hz), 21.4 (d, JC−F = 5.6 Hz), 20.2.
19F NMR (376 MHz, D2O) δ −74.2 (TFA), −217.8. Anal. Calcd for
C15H18FN3O2·1.65TFA·1.5H2O (FW 506): C, 43.40; H, 4.51; F,
22.32; N, 8.30. Found: C, 43.36; H, 4.13; F, 22.05; N, 7.91.
4-[2-[5-[5-(2(S)-Azetidinylmethoxy)-3-pyridinyl]-3-isoxazolyl]-
ethyl]morpholine (27). This compound was obtained from 14
employing methods D, E, and B and gradient II; colorless oil; yield
63% over three steps; purity 99.4%; [α]D
20 −4.5 (c = 0.62, MeOH).
1H NMR (400 MHz, D2O) δ 8.95 (s, 1H), 8.70 (s, 1H), 8.58 (s, 1H),
7.16 (s, 1H), 5.04−5.02 (m, 1H), 4.65 (d, 2H, J = 2.0 Hz), 4.18−4.10
(m, 1H), 3.85 (t, 2H, J = 12.4 Hz), 3.68−3.62 (m, 4H), 3.37−3.26 (m,
4H), 2.73 (q, 2H, J = 12.4 Hz). 13C NMR (100 MHz, D2O) δ 163.4,
162.2 (TFA), 160.8, 156.3, 131.9, 130.4, 127.3, 127.1, 115.8 (TFA),
103.9, 63.2, 58.1, 53.9, 51.4, 43.3, 20.2, 19.8. Anal. Calcd for
C18H24N4O3·2.95TFA·0.65H2O (FW 692): C, 41.45; H, 4.11; F,
24.28; N, 8.09. Found: C, 41.07; H, 3.73; F, 23.91; N, 7.90.
4-[2-[5-[5-(2(S)-Pyrrolidinylmethoxy)-3-pyridinyl]-3-isoxazolyl]-
ethyl]morpholine (28). This compound was obtained from 19
employing methods D, E, and B and gradient II; colorless oil; yield
57% over three steps; purity 98.8%; [α]D
20 −1.4 (c = 0.36, MeOH).
1H NMR (400 MHz, D2O) δ 8.89 (s, 1H, J = 2.0 Hz), 8.64 (d, 1H, J =
2.0 Hz), 8.54 (s, 1H), 7.14 (s, 1H), 4.68−4.66 (m, 1H), 4.47 (m, 1H),
4.15−4.11 (m, 3H), 3.83 (t, 2H, J = 12.4 Hz), 3.66−3.60 (m, 4H),
3.42 (t, 2H, J = 7.2 Hz), 3.35−3.28 (m, 4H), 2.32−2.30 (m, 1H),
2.17−2.09 (m, 1H), 2.00−1.98 (m, 1H). 13C NMR (100 MHz, D2O)
δ 163.3, 162.2 (TFA), 160.8, 156.2, 131.7, 130.2, 127.3, 127.1, 115.6
(TFA), 103.9, 99.6, 67.8, 63.2, 57.9, 53.9, 51.4, 45.6, 25.3, 23.0, 20.2.
Anal. Calcd for C19H26N4O3·3TFA·0.5H2O: H, 42.32; C, 4.26; F, 24.1;
N, 7.90. Found: C, 42.34; H, 4.15; F, 24.07; N, 7.79.
Ethylcarbamic Acid 2-[5-[5-(2(S)-Azetidinylmethoxy)-3-pyridinyl]-
3-isoxazolyl]ethyl Ester (29). This compound was obtained from 14
and ethyl isocyanate employing methods F and B and gradient I;
cfolorless oil; yield 77% over two steps; purity 99.5%; [α]D
20 −3.6 (c =
0.39, MeOH). 1H NMR (400 MHz, D2O) δ 8.87 (s, 1H), 8.70 (s,
1H), 8.50 (s, 1H), 7.11 (s, 1H), 5.03−4.99 (m, 1H), 4.63 (d, 2H, J =
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3.6 Hz), 4.29 (t, 2H, J = 5.6 Hz), 4.19−4.06 (m, 2H), 3.05−2.96 (m,
4H), 2.71 (q, 2H, J = 8.4 Hz), 0.95 (t, 2H, J = 7.2 Hz). 13C NMR (100
MHz, D2O) δ 162.7, 161.8 (TFA), 157.4, 156.2, 131.9, 130.5, 127.1,
126.8, 115.8 (TFA), 104.1, 67.6, 61.9, 58.1, 43.3, 35.0, 25.2, 19.8, 13.6.
Anal. Calcd for C17H22N4O4·2.05TFA·0.15H2O (FW 583): C, 43.48;
H, 4.21; F, 20.05; N, 9.61. Found: C, 43.43; H, 4.03; F, 19.87; N, 9.67.
Ethylcarbamic Acid 2-[5-[5-(2(S)-Pyrrolidinylmethoxy)-3-pyridin-
yl]-3-isoxazolyl]ethyl Ester (30). This compound was obtained from
19 and ethyl isocyanate employing methods F and B and gradient I;
colorless oil; yield 42% over two steps; purity 99.8%; [α]D
20 2.2 (c =
0.36, MeOH). 1H NMR (400 MHz, D2O) δ 8.76 (s, 1H), 8.54 (d, 1H,
J = 2.0 Hz), 8.41 (s, 1H), 7.03 (s, 1H), 4.59−4.55 (m, 1H), 4.38 (t,
1H, J = 7.6 Hz), 4.21 (t, 2H, J = 6.0 Hz), 4.10−4.08 (m, 2H), 3.32 (t,
2H, J = 6.8 Hz), 2.97−2.87 (m, 4H), 2.22 (m, 1H), 2.06−1.90 (m,
2H), 1.89−1.84 (m, 1H), 0.86 (t, 3H, J = 7.2 Hz). 13C NMR (100
MHz, D2O) δ 162.6, 162.5, 161.8 (TFA), 157.4, 156.2, 131.4, 129.9,
127.3, 127.2, 115.7 (TFA), 104.2, 67.8, 61.9, 57.8, 45.5, 35.0, 25.3,
25.1, 22.9, 13.5. Anal. Calcd for C18H24N4O4·2.65TFA·0.95H2O (FW
680): C, 41.17; H, 4.23; F, 22.22; N, 8.24. Found: C, 40.89; H, 3.94; F,
22; N, 8.12.
Phenylcarbamic Acid 2-[5-[5-(2(S)-Azetidinylmethoxy)-3-pyridin-
yl]-3-isoxazolyl]ethyl Ester (31). This compound was obtained from
14 and phenyl isocyanate employing methods F and B and gradient I;
colorless oil; yield 31% over two steps; purity 99.2%; [α]D
20 −2.5 (c =
0.28, MeOH). 1H NMR (400 MHz, D2O) δ 8.71 (s, 1H), 8.55 (d, 1H,
J = 2.0 Hz), 8.30 (s, 1H), 7.17−7.10 (m, 4H), 7.00 (s, 1H), 6.95 (t,
1H, J = 6.8 Hz), 5.00−4.97 (m, 1H), 4.50 (d, 2H, J = 3.6 Hz), 4.38 (t,
2H, J = 6.0 Hz), 4.17−4.07 (m, 2H), 3.09 (t, 2H, J = 6.0 Hz), 2.71−
2.66 (m, 2H). 13C NMR (100 MHz, D2O) δ 162.7, 162.5, 162.2
(TFA), 155.9, 154.6, 136.9, 131.9, 130.4, 128.6, 126.9, 126.3, 123.3,
118.7, 115.8 (TFA), 104.0, 67.5, 62.2, 58.1, 43.3, 25.1, 19.9. Anal.
Calcd for C21H22N4O4·1.8TFA·0.05H2O (FW 600): C, 49.20; H, 4.01;
F, 17.08; N, 9.33. Found: C, 49.23; H, 3.98; F, 17.07; N, 9.31.
Phenylcarbamic Acid 2-[5-[5-(2(S)-Pyrrolidinylmethoxy)-3-pyri-
dinyl]-3-isoxazolyl]ethyl Ester (32). This compound was obtained
from 19 and phenyl isocyanate employing methods F and B and
gradient I; colorless oil; yield 88% over two steps; purity 99.0%; [α]D
20
2.7 (c = 0.22, MeOH). 1H NMR (400 MHz, D2O) δ 8.72 (s, 1H), 8.52
(s, 1H), 8.13 (s, 1H), 7.05−6.95 (m, 4H), 6.88 (s, 1H), 6.78−6.76 (m,
1H), 4.42−4.39 (m, 1H), 4.28−4.23 (m, 3H), 4.04−4.02 (m, 1H),
3.34 (t, 2H, J = 7.2 Hz), 2.95 (t, 2H, J = 5.6 Hz), 2.22−2.18 (m, 1H),
2.07−1.99 (m, 2H), 1.86−1.81 (m, 2H). 13C NMR (100 MHz, D2O)
δ 162.4, 162.3, 162.4 (TFA), 155.9, 154.1, 137.0, 131.3, 129.9, 128.4,
126.8, 126.3, 123.0, 118.3, 115.8 (TFA), 104.1, 67.6, 62.0, 57.8, 45.5,
25.4, 25.0, 22.9. Anal. Calcd for C22H24N4O4·2TFA (FW 636): C,
49.06; H, 4.12; F, 17.91; N, 8.80. Found: C, 49.15; H, 4.12; F, 18.18;
N, 8.97.
3-(Benzyloxy)-5-ethynylpyridine (34). To a stirred solution/
suspension of 33 (1.85 g, 7.0 mmol), PPh3 (605 mg, 2.3 mmol),
and CuI (530 mg, 2.8 mmol) in Et3N (30 mL) was added
PdCl2(PPh3)2 (490 mg, 0.70 mmol). The mixture was stirred at
room temperature for 30 min under argon, and then ethynyl-
(trimethyl)silane (3.0 mL, 21.3 mmol) was added. After stirring at 60
°C for 24 h, the reaction mixture was concentrated. The residue was
purified by CC on SiO2 (hexane/acetone 3:1) to give the
trimethylsilylalkyne (1.60 g, 81%) as a pale-brown solid. 1H NMR
(400 MHz, CDCl3) δ 8.31 (s, 1H), 8.30 (s, 1H), 7.43−7.31 (m, 6H),
5.03 (s, 2H), 3.21 (s, 1H).
To a solution of the above trimethylsilylalkyne (1.40 g, 5.0 mmol)
in 10 mL of THF, 1 M TBAF in THF (8 mL) was added under argon
with ice cooling. After stirring at rt for 1 h, the reaction mixture was
quenched with water and extracted with EtOAc (2 × 30 mL). The
combined organic layers were washed with brine, dried over Na2SO4,
and evaporated. The residue was purified by CC on SiO2 (hexane/
EtOAc 4:1) to afford the desired product (750 mg, 72%) as white
solid. 1H NMR (400 MHz, CDCl3) δ 8.34 (s, 1H), 8.33 (s, 1H), 7.39−
7.24 (m, 6H), 5.03 (s, 2H), 3.21 (s, 1H). 13C NMR (100 MHz,
CDCl3) δ 154.1, 145.3, 138.5, 135.7, 128.8, 128.4, 127.5, 124.0, 119.4,
80.7, 80.2, 70.3.
3-(Benzyloxy)-5-(3-ethyl-5-isoxazolyl)pyridine (35). This com-
pound was obtained from 34 and 1-nitropropane employing method
A; pale-yellow oil; yield 72%. 1H NMR (400 MHz, CDCl3) δ 8.56 (s,
1H), 8.37 (s, 1H), 7.59 (s, 1H), 7.42−7.18 (m, 5H), 6.44 (s, 1H), 5.11
(s, 2H), 2.57 (q, 2H, J = 7.6 Hz), 1.29 (t, 3H, J = 7.6 Hz). 13C NMR
(100 MHz, CDCl3) δ 166.1, 165.5, 154.5, 139.3, 139.0, 135.3, 128.4,
128.0, 127.2, 117.3, 99.8, 70.1, 19.2, 12.2.
3-(Benzyloxy)-5-[3-(3,3,3-trifluoropropyl)-5-isoxazolyl]pyridine
(36). This compound was obtained from 30 and 1,1,1-trifluoro-4-
nitrobutane employing method A; pale-yellow oil; yield 72%. 1H NMR
(400 MHz, CDCl3) δ 8.59 (s, 1H), 8.44 (d, 1H, J = 2.8 Hz), 7.63 (t,
1H, J = 2.2 Hz), 7.46−7.26 (m, 5H), 6.49 (s, 1H), 5.18 (s, 2H), 3.01
(m, 2H), 2.59 (m, 2H).
3-(Benzyloxy)-5-[3-[2-[tert-Butyl(dimethyl)silanyloxy]ethyl]-5-
isoxazolyl]pyridine (37). This compound was obtained from 30 and 9
employing method A; pale-yellow oil; yield 86%. 1H NMR (400 MHz,
CDCl3) δ 8.56 (s, 1H), 8.38 (s, 1H), 7.59 (s, 1H), 7.42−7.29 (m, 5H),
6.54 (s, 1H), 5.07 (s, 2H), 3.91 (t, 2H, J = 6.0 Hz), 2.91 (t, 2H, J = 6.0
Hz), 0.88 (s, 9H), 0.03 (s, 6H).
3-(2(S)-Azetidinylmethoxy)-5-(3-ethyl-5-isoxazolyl)pyridine (38).
This compound was obtained from 35 and 2(S)-(hydroxymethyl)-
azetidine-1-carboxylic acid tert-butyl ester employing methods G, H,
and B and gradient I; colorless oil; yield 11% over three steps; purity
99.4%; [α]D
20 −4.2 (c = 1.11, MeOH). 1H NMR (400 MHz, D2O) δ
8.88 (s, 1H), 8.65 (s, 1H), 8.53 (s, 1H), 7.03 (s, 1H), 5.00 (m, 1H),
4.62 (d, 2H, J = 4.0 Hz), 4.17−4.04 (m, 2H), 2.75−2.67 (m, 4H), 1.23
(t, 3H, J = 7.6 Hz). 13C NMR (100 MHz, D2O) δ 167.6, 162.5, 162.6
(TFA), 156.6, 132.0, 130.3, 127.9, 127.6, 116.1 (TFA), 104.2, 68.0,
5 8 . 5 , 4 3 . 6 , 2 0 . 2 , 1 9 . 0 , 1 1 . 5 . A n a l . C a l c d f o r
C14H17N3O2·2.3TFA·0.9H2O (FW 538): C, 41.54; H, 3.95; F,
24.38; N, 7.81. Found: C, 41.73; H, 3.84; F, 24.39; N, 7.62.
3-(2(S)-Azetidinylmethoxy)-5-[3-(3,3,3-trifluoropropyl)-5-
isoxazolyl]pyridine (39). This compound was obtained from 36 and
2(S)-(hydroxymethyl)azetidine-1-carboxylic acid tert-butyl ester em-
ploying methods G, H, and B and gradient I; colorless oil; yield 12.5%
over three steps; purity 99.7%; [α]D
20 −3.3 (c = 0.81, MeOH). 1H
NMR (400 MHz, D2O) δ 8.84 (s, 1H), 8.60 (s, 1H), 8.49 (s, 1H), 7.03
(s, 1H), 4.93 (m, 1H), 4.56 (m, 2H), 4.04 (m, 2H), 2.95 (t, 2H, J = 7.4
Hz), 2.63 (m, 2H), 2.54 (m, 2H). 13C NMR (100 MHz, D2O) δ 163.7,
163.0, 162.2 (TFA), 156.7, 131.9, 130.7, 127.4, 126.1 (q, JC−F = 229.0
Hz), 116.0 (TFA), 104.3, 68.0, 58.4, 43.6, 30.9 (q, JC−F = 29.0 Hz),
20.2, 18.6. Anal. Calcd for C15H16F3N3O2·2.75TFA·1.05H2O (FW
613): C, 37.32; H, 3.19; F, 32.39; N, 6.37. Found: C, 37.25; H, 2.96; F,
32.18; N, 6.35.
2-(Hydroxymethyl)-3-azabicyclo[3.1.0]hexane-3-carboxylic Acid
tert-Butyl Ester (41). To a solution of 40 (250 mg, 2 mmol) in 40
mL of half-saturated NaHCO3 solution was added dropwise with ice
cooling Boc2O (870 mg, 4 mmol) in H2O (11 mL) and THF (5 mL).
After stirring overnight at rt, the solvent was evaporated. HCl (2 M, 20
mL) was added with ice cooling, and then the mixture was extracted
with CH2Cl2 (3 × 10 mL). The combined CH2Cl2 phases were dried
over Na2SO4 and concentrated to obtain 3-azabicyclo[3.1.0]hexane-
2,3-dicarboxylic acid 3-tert-butyl ester, which was carried on without
further purification.
To the solution of this intermediate in anhydrous THF (20 mL),
BH3·THF in THF (1 M, 3 mL) was added under argon with ice
cooling. After stirring at rt for 2 h, the reaction mixture was quenched
with satd NH4Cl. The phases were separated, and the organic phase
was washed with water and brine, dried over Na2SO4, and
concentrated to obtain the title compound; colorless oil; yield 310
mg (73%) over two steps. 1H NMR (400 MHz, CDCl3) δ 5.52 (br,
1H), 3.88 (m, 1H), 3.74 (m, 1H), 3.56 (m, 1H), 3.42−3.37 (m, 3H),
1.55 (m, 1H), 1.37 (s, 9H), 0.48 (m, 1H), 0.27 (m, 1H).
2-[5-[5-[(3(S,R)-Azabicyclo[3.1.0]-2(S)-hexyl)methoxy]-3-pyridin-
yl]-3-isoxazolyl]ethane (42). This compound was obtained from 35
and 41 employing methods G, H, and B and gradient I; colorless oil;
yield 20% over three steps; purity 99.6%; [α]D
20 0 (c = 0.48, MeOH).
1H NMR (400 MHz, D2O) δ 8.89 (s, 1H), 8.63 (s, 1H), 8.50 (s, 1H),
7.06 (s, 1H), 4.50−4.33 (m, 2H), 3.61−3.52 (m, 2H), 2.77 (q, 2H, J =
7.6 Hz), 1.95 (m, 2H), 1.26 (t, 3H, J = 7.6 Hz), 0.92 (m, 1H), 0.65 (m,
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1H). 13C NMR (100 MHz, D2O) δ 167.3, 162.4 (TFA), 162.3, 156.1,
131.9, 130.1, 127.4, 126.9, 117.4 (TFA), 103.7, 67.8, 58.9, 47.4, 18.6,
15.6, 13.7, 11.1, 3.5. Anal. Calcd for C16H19N3O2·2.6TFA·0.9H2O
(FW 554): C, 42.58; H, 3.94; F, 24.78; N, 7.03. Found: C, 42.25; H,
3.59; F, 24.50; N, 6.79.
2-[5-[5-[(3(S,R)-Azabicyclo[3.1.0]-2(S)-hexyl)methoxy]-3-pyridin-
yl]-3-isoxazolyl]ethanol (43). This compound was obtained from 37
and 41 employing methods G, H, and B and gradient I; colorless oil;
yields of individual steps 72%, 61%, and 64%; purity 99.8%; [α]D
20
−0.4 (c = 0.48, MeOH). 1H NMR (400 MHz, D2O) δ 8.88 (s, 1H),
8.71 (s, 1H), 8.50 (s, 1H), 7.08 (s, 1H), 4.47−4.39 (m, 2H), 3.91 (t,
2H, J = 6.0 Hz), 3.57−3.48 (m, 2H), 2.96 (t, 2H, J = 5.8 Hz), 1.91 (m,
2H), 0.87 (m, 2H), 0.63 (m, 1H). 13C NMR (100 MHz, D2O) δ
163.7, 162.9, 162.5 (TFA), 156.6, 132.1, 130.4, 127.7, 127.4, 116.2
(TFA), 104.5, 68.2, 59.3, 47.7, 28.4, 15.9, 14.1, 3.9. Anal. Calcd for
C16H19N3O3·2.5TFA·0.3H2O (FW 549): C, 42.29; H, 3.76; F, 24.08;
N, 7.10. Found: C, 42.29; H, 3.36; F, 23.68; N, 6.92.
General Procedures for Binding and Functional Studies. In
Vitro Binding Studies. [3H]Epibatidine competition studies and
broad-range screening were carried out by the National Institute of
Mental Health’s Psychoactive Drug Screening Program, contract no.
HHSN-271-2008-00025-C (NIMH PDSP). For experimental details,
please refer to the PDSP Web site http://pdsp.med.unc.edu/.
Cell Lines and Culture. Cell lines naturally or heterologously
expressing specific, functional, human nAChR subtypes were used.
The human clonal cell line TE671/RD naturally expresses human
muscle-type α1*-nAChRs, containing α1, β1, γ, and δ subunits, with
function detectable using 86Rb+ efflux assays.23 The human neuro-
blastoma cell line SH-SY5Y naturally expresses autonomic α3β4*-
nAChRs, containing α3, β4, probably α5, and sometimes β2 subunits
and also displays function detectable using 86Rb+ efflux assays.24 SH-
SY5Y cells also express homopentameric α7-nAChRs. However, their
function is not detected in the 86Rb+ efflux assay under the conditions
used. SH-EP1 human epithelial cells stably transfected with human α4
and β2 subunits (SH-EP1-hα4β2 cells) have been established and the
human α4β2-nAChRs that they stably and heterologously express have
been characterized with both ion flux and radioligand binding assays.25
TE671/RD, SH-SY5Y, and transfected SH-EP1 cell lines were
maintained as low passage number (1−26 from our frozen stocks)
cultures to ensure stable expression of native or heterologously
expressed nAChRs as previously described.23 Cells were passaged once
a week by splitting just-confluent cultures 1/300 (TE671/RD), 1/10
(SH-SY5Y), or 1/40 (transfected SH-EP1) in serum-supplemented
medium to maintain log-phase growth.
86Rb+ Efflux Assays. Function of nAChR subtypes was investigated
using an established 86Rb+ efflux assay protocol.23 The assay is specific
for nAChR function under the conditions used, for example, giving
identical results in the presence of 100 nM atropine to exclude possible
contributions of muscarinic acetylcholine receptors. Cells harvested at
confluence from 100 mm plates under a stream of fresh medium only
(SH-SY5Y cells) or after mild trypsinization (Irvine Scientific, USA;
for TE671/RD or transfected SH-EP1 cells) were then suspended in
complete medium and evenly seeded at a density of 1.25−2 confluent
100 mm plates per 24-well plate (Falcon; ∼100−125 mg of total cell
protein per well in a 500 μL volume; poly L-lysine-coated for SH-SY5Y
cells). After cells had adhered generally overnight, but no sooner than
4 h later, the medium was removed and replaced with 250 μL per well
of complete medium supplemented with ∼350000 cpm of 86Rb+
(NEN; counted at 40% efficiency using Cerenkov counting and the
Packard TriCarb 1900 liquid scintillation analyzer). After at least 4 h
and typically overnight, 86Rb+ efflux was measured using the “flip-
plate” technique. Briefly, after aspiration of the bulk of 86Rb+ loading
medium from each well of the “cell plate,” each well containing cells
was rinsed with 2 mL of fresh 86Rb+ efflux buffer (130 mM NaCl, 5.4
mM KCl, 2 mM CaCl2, 5 mM glucose, and 50 mM HEPES; pH 7.4)
to remove extracellular 86Rb+. Following removal of residual rinse
buffer by aspiration, the flip-plate technique was used again to
simultaneously introduce 1.5 mL of fresh efflux buffer containing drugs
of choice at indicated final concentrations from a 24-well “efflux/drug
plate” into the wells of the cell plate. After a 9.5 min incubation, the
solution was “flipped” back into the efflux/drug plate, and any
remaining buffer in the cell plate was removed by aspiration. Ten min
after the initiation of the first drug treatment, a second efflux/drug
plate was used to reintroduce the same concentrations of drugs of
choice with the addition of an ∼EC90 concentration of the full agonist
carbamylcholine for 5 min (∼EC90 concentrations were 200 μM for
SH-EP1-hα4β2 cells, 2 mM for SHSY5Y cells, and 464 mM for
TE671/RD cells). The second drug treatment was then flipped back
into its drug plate, and the remaining cells in the cell plate were lysed
and suspended by addition of 1.5 mL of 0.1 M NaOH with 0.1%
sodium dodecyl sulfate to each well. Suspensions in each well were
then subjected to Cerenkov counting (Wallac Micobeta Trilux 1450;
25% efficiency) after placement of inserts (Wallac 1450−109) into
each well to minimize cross-talk between wells.
For quality control and normalization purposes, the sum of 86Rb+ in
cell plates and efflux/drug plates was defined to confirm material
balance (i.e., that the sum of 86Rb+ released into the efflux/drug plates
and 86Rb+ remaining in the cell plate were the same for each well).
Similarly, the sum of 86Rb+ in cell plates and efflux/drug plates also
determined the efficiency of 86Rb+ loading (the percentage of applied
86Rb+ actually loaded into cells). Furthermore, the sum of 86Rb+ in cell
plates and the second efflux/drug plates defined the amount of
intracellular 86Rb+ available at the start of the second 5 min assay and
were used to normalize nAChR function assessed.
For each experiment, in one set of control samples, total 86Rb+
efflux was assessed in the presence of a fully efficacious concentration
of carbamylcholine alone (1 mM for SH-EP1-hα4β2 and TE671/RD
cells, or 3 mM for SH-SY5Y cells). Nonspecific 86Rb+ efflux in another
set of control samples was measured either in the presence of the fully
efficacious concentration of carbamylcholine plus 100 μM mecamyl-
amine, which gave full block of agonist-induced and spontaneous
nAChR-mediated ion flux, or in the presence of efflux buffer alone.
Both determinations of nonspecific efflux were equivalent. Specific
efflux was then taken as the difference in control samples between total
and nonspecific 86Rb+ efflux. The same approaches were used to define
total, nonspecific, and specific ion flux responses in samples subjected
to the second 5 min exposure to test drug with or without
carbamylcholine at its ∼EC90 concentration.
Intrinsic agonist activity of test drugs was ascertained during the first
9.5 min of the initial 10 min exposure period using samples containing
test drug only at different concentrations and was normalized, after
subtraction of nonspecific efflux, to specific efflux in carbamylcholin
control samples. Specific 86Rb+ efflux elicited by test drug as a
percentage of specific efflux in carbamylcholine controls was the same
in these samples whether measured in absolute terms or as a
percentage of loaded 86Rb+. Even in samples previously giving an efflux
response during the initial 10 min exposure to a partial or full agonist,
residual intracellular 86Rb+ was adequate to allow assessment of
nAChR function in the secondary 5 min assay. However, care was
needed to ensure that data were normalized to the amount of
intracellular 86Rb+ available at the time of the assay, as absolute levels
of total, nonspecific, or specific efflux varied in cells partially depleted
of intracellular 86Rb+ due to action of any agonist present during the
10 min drug exposure period. That is, calculations of specific efflux as a
percentage of loaded 86Rb+ typically were corrected for any variation in
the electrochemical gradient of 86Rb+ created by intracellular ion
depletion after the first (agonism/pretreatment) drug treatment.
Ion flux assays (n ≥ 3 separate studies for each drug and cell line
combination) were fit to the Hill equation, F = Fmax/(1 + (X/EC50)
n),
where F is the percentage of control, Fmax, for EC50 (n > 0 for agonists)
or IC50 (n < 0 for antagonists) values using Prism 4 (GraphPad, San
Diego, USA). Most ion flux data were fit allowing maximum and
minimum ion flux values to be determined by curve fitting but in some
cases, where antagonists or agonists had weak functional potency,
minimum ion flux was set at 0% of control or maximum ion flux was
set at 100% of control, respectively.
Determinations of ligand agonist efficacy at HS or LS α4β2-nAChR
were made by extrapolations of results in each of several experiments
plotting the maximal efficiacy of the test ligand against the efficacy of 1
μM compound 2, which is a full agonist at HS α4β2-nAChRs but
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inactive at LS α4β2-nAChRs. These two α4β2-nAChR isoforms are
spontaneously expressed in different ratios in cells assayed in different
experiments performed with different cell batches. However,
determinations of compound 2 efficacy relative to that of carbamylcho-
line, which is the reference full agonist at both receptor isoforms, can
be used to define the response proportion due to compound 2-
activated HS α4β2-nAChRs in the cells being studied (typically
varying from 25 to 60%). Thus, extrapolation of results for efficacy of
the test ligand on one axis to the origin (0% compound 2 response or
HS α4β2-nAChR expression) or the maximum extreme (100%
compound 2 response or HS α4β2-nAChR expression) on the other
axis allows separate determination of the test ligand’s activity if it were
acting a pure populations of LS or HS α4β2-nAChRs. Just as is the
case for compound 2, the test ligands are partial agonists at the mixture
of α4β2-nAChR isoforms because they are inactive (efficiacy ∼0% of
that of a full agonist) at LS α4β2-nAChR but active at HS α4β2-
nAChR, usually with an efficacy at the latter that is less than or
comparable to that of compound 2 (Table 2).
General Procedures for Behavioral Studies. Animals. BALB/cJ
male mice (8−10 weeks old at testing) were obtained from Jackson
Laboratory (Bar Harbor, ME, USA). Mice were housed four to a cage
in a colony room maintained at 22 ± 2 °C on a 12 h light−dark cycle.
All animal experiments were conducted in accordance with the NIH
Guide for the Care and Use of Laboratory Animals and the
PsychoGenics Animal Care and Use Committee.
Drugs. Compounds 25, 26, and 38 were synthesized as described
above, and sertraline was purchased from Toronto Research Chemicals
(Ontario, Canada). All compounds were dissolved in water and
administered by intraperitoneal (IP) injection in a volume of 10 mL/
kg.
Mouse Forced Swim Test. Procedures were based on those
previously described.25 Mice were individually placed into clear glass
cylinders (15 cm tall ×10 cm wide, 1 L beakers) containing 23 ± 1 °C
water 12 cm deep (approximately 800 mL). Mice were administered
vehicle, the SSRI sertraline (20 mg/kg) as a positive control, or test
compound (25, 26, or 38; 5, 10, 30 mg/kg. Compound 38 was also
tested at 1 and 3 mg/kg.) Thirty minutes following IP administration,
mice were placed in the water, and the time the animal spent immobile
was recorded over a 6 min trial. Immobility was defined as the postural
position of floating in the water.
Statistical Analysis. Data were analyzed with Analysis of Variance
(ANOVA) with treatment group (vehicle, sertraline, or compound 25,
26, or 38) as the between-group variable and total time immobile
(seconds over the 6 min trial) as the dependent variable. Significant
main effects were followed up with the post hoc Fisher’s LSD test.
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